PROCHIMIA SURFACES SP. Z O.O.

Their core work

ProChimia Surfaces is a Polish SME specializing in functional surface chemistry and nanomaterial coatings, with a strong focus on biomedical applications. They design and manufacture surface-modified nanoparticles and functionalized substrates used in drug delivery, gene editing, and cancer therapy research. Their core capability lies in engineering the surface properties of nanoscale materials — making nanoparticles biocompatible, targetable, and programmable for clinical use. Across their H2020 portfolio, they consistently serve as the surface chemistry specialist enabling partners to translate nanoparticle research into viable medical technologies.

What they specialise in

How they've shifted over time

ProChimia's trajectory shows a clear shift from nanomanufacturing processes toward advanced biomedical applications. Their earliest project (NANOFACTURING, 2015) focused on scaling up nanoparticle production for clinical use — an industrial manufacturing challenge. By 2018-2019, they moved decisively into therapeutic applications: first programmable cancer therapies using evolutionary algorithms (EVO-NANO), then gene editing via nanotransducers (I-GENE). The progression is from "how to make nanomaterials at scale" to "how to use functionalized nanomaterials to treat disease in living organisms."

ProChimia is moving upstream from manufacturing nanoparticles to engineering them as precision delivery vehicles for gene therapies and targeted cancer treatments — positioning them at the intersection of nanotechnology and advanced therapeutics.

How they like to work

ProChimia operates exclusively as a specialist partner, never as a coordinator — consistent with their role as a niche surface chemistry provider rather than a project driver. They work in research-intensive consortia (all RIA projects) with an average of 7+ partners per project, contributing deep technical capability rather than project management. With 20 unique partners across 8 countries from just 3 projects, they connect broadly rather than repeatedly with the same groups, suggesting they are sought after for their specific expertise.

ProChimia has collaborated with 20 unique partners across 8 countries through their 3 H2020 projects, giving them a wide European network relative to their size. As a specialist SME, they connect research institutions and clinical partners who need surface-functionalized nanomaterials.

What sets them apart

ProChimia occupies a rare niche: they are a commercial SME that manufactures custom surface chemistries for nanomaterials, bridging the gap between academic nanoparticle research and real-world biomedical products. Few companies in Europe offer this combination of surface functionalization expertise with the flexibility to work across cancer therapy, gene editing, and scalable manufacturing. For consortium builders, they bring a production-ready partner who understands both the chemistry and the path to clinical application — not just a lab, but a company that can supply functionalized materials at meaningful scale.

Highlights from their portfolio

• I-GENE
  Their largest funded project (EUR 613,850) and most forward-looking — applying nanotransducers for in-vivo genome editing, a frontier therapeutic area.
• EVO-NANO
  Unusual combination of evolutionary algorithms and nanoparticle cancer therapy, targeting both colon and breast cancer stem cells with programmable drug delivery.
• NANOFACTURING
  Addressed the critical manufacturing scale-up gap for clinically relevant nanomaterials — the practical challenge that blocks most nano-therapies from reaching patients.